Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection
Authors:
- 16 September 2020
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (9)
Abstract
Background COVID‐19 infection poses a serious risk to patients and – due to its contagious nature – to those healthcare workers (HCWs) treating them. If the mouth and nose of HCWs are irrigated with antimicrobial solutions, this may help reduce the risk of active infection being passed from infected patients to HCWs through droplet transmission or direct contact. However, the use of such antimicrobial solutions may be associated with harms related to the toxicity of the solutions themselves, or alterations in the natural microbial flora of the mouth or nose. Understanding these possible side effects is particularly important when the HCWs are otherwise fit and well. Objectives To assess the benefits and harms of antimicrobial mouthwashes and nasal sprays used by healthcare workers (HCWs) to protect themselves when treating patients with suspected or confirmed COVID‐19 infection. Search methods Information Specialists from Cochrane ENT and Cochrane Oral Health searched the Central Register of Controlled Trials (CENTRAL 2020, Issue 6); Ovid MEDLINE; Ovid Embase and additional sources for published and unpublished trials. The date of the search was 1 June 2020. Selection criteria This is a question that urgently requires evidence, however at the present time we did not anticipate finding many completed randomised controlled trials (RCTs). We therefore planned to include the following types of studies: RCTs; quasi‐RCTs; non‐randomised controlled trials; prospective cohort studies; retrospective cohort studies; cross‐sectional studies; controlled before‐and‐after studies. We set no minimum duration for the studies. We sought studies comparing any antimicrobial mouthwash and/or nasal spray (alone or in combination) at any concentration, delivered to HCWs, with or without the same intervention being given to the patients with COVID‐19. Data collection and analysis We used standard Cochrane methodological procedures. Our primary outcomes were: 1) incidence of symptomatic or test‐positive COVID‐19 infection in HCWs; 2) significant adverse event: anosmia (or disturbance in sense of smell). Our secondary outcomes were: 3) viral content of aerosol, when present (if intervention administered to patients); 4) other adverse events: changes in microbiome in oral cavity, nasal cavity, oro‐ or nasopharynx; 5) other adverse events: allergy, irritation/burning of nasal, oral or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding), long‐term staining of mucous membranes or teeth, accidental ingestion. We planned to use GRADE to assess the certainty of the evidence for each outcome. Main results We found no completed studies to include in this review. We identified three ongoing studies (including two RCTs), which aim to enrol nearly 700 participants. The interventions included in these trials are povidone iodine, nitric oxide and GLS‐1200 oral spray (the constituent of this spray is unclear and may not be antimicrobial in nature). Authors' conclusions We identified no studies for inclusion in this review. This is not surprising given the relatively recent emergence of COVID‐19 infection. It is promising that the question posed in this review is being addressed by two RCTs and a non‐randomised study. We are concerned that only one of the ongoing studies specifically states that it will evaluate adverse events and it is not clear if this will include changes in the sense of smell or to the oral and nasal microbiota, and any consequences thereof. Very few interventions have large and dramatic effect sizes. If a positive treatment effect is demonstrated when studies are available for inclusion in this review, it may not be large. In these circumstances in particular, where those receiving the intervention are otherwise fit and well, it may be a challenge to weigh up the benefits against the harms if the latter are of uncertain frequency and severity.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trialRespiratory Research, 2015
- Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)Infectious Diseases and Therapy, 2015
- Vitamin D3and gargling for the prevention of upper respiratory tract infections: a randomized controlled trialBMC Infectious Diseases, 2014
- Efficacy of a Carrageenan nasal spray in patients with common cold: a randomized controlled trialRespiratory Research, 2013
- Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common coldBMC Complementary and Alternative Medicine, 2012
- Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common coldRespiratory Research, 2010
- Can We Prevent Influenza-like Illnesses by Gargling?Internal Medicine, 2007
- Inactivation of SARS Coronavirus by Means of Povidone-Iodine, Physical Conditions and Chemical ReagentsDermatology, 2006
- Prevention of Upper Respiratory Tract Infections by GarglingA Randomized TrialAmerican Journal of Preventive Medicine, 2005
- In vitro Virucidal Effectiveness of a 0.12%-Chlorhexidine Gluconate MouthrinseJournal of Dental Research, 1990